SNDX Syndax Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SNDX

Price (delayed)

$18.02

Market cap

$1.6B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.79

Enterprise value

$1.81B

?
Relative Growth: Rel. Growth: 65
Relative Strength: Rel. Strength: 58
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 34

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab, ...

Highlights
The EPS is up by 28% year-on-year and by 15% since the previous quarter
The net income has grown by 27% YoY and by 15% from the previous quarter
The quick ratio has grown by 22% from the previous quarter but it has contracted by 14% YoY
SNDX's equity has shrunk by 81% YoY and by 36% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.syndax.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of SNDX

SNDX stock price

How has the Syndax Pharmaceuticals stock price performed over time
Intraday
-1.74%
1 week
-8.76%
1 month
-9.72%
1 year
64.42%
YTD
-14.23%
QTD
-22.86%

Financial performance

How have Syndax Pharmaceuticals's revenue and profit performed over time
Revenue
$217.42M
Gross profit
$208.7M
Operating income
-$223.53M
Net income
-$243.25M
Gross margin
96%
Net margin
-111.9%
The operating margin has surged by 87% year-on-year and by 35% since the previous quarter
SNDX's net margin has soared by 85% YoY and by 32% from the previous quarter
The operating income has grown by 35% YoY and by 18% from the previous quarter
The net income has grown by 27% YoY and by 15% from the previous quarter

Price vs fundamentals

How does SNDX's price correlate with its fundamentals

Growth

What is Syndax Pharmaceuticals's growth rate over time

Valuation

What is Syndax Pharmaceuticals stock price valuation
P/E
N/A
P/B
38.19
P/S
7.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.33
The EPS is up by 28% year-on-year and by 15% since the previous quarter
SNDX's equity has shrunk by 81% YoY and by 36% QoQ
SNDX's price to book (P/B) is 65% higher than its last 4 quarters average of 23.6
The stock's P/S is 30% below its last 4 quarters average of 10.6
The revenue has grown by 26% from the previous quarter

Efficiency

How efficient is Syndax Pharmaceuticals business performance
The company's return on equity has shrunk by 153% YoY and by 24% QoQ
The return on sales has surged by 87% year-on-year and by 35% since the previous quarter
The return on invested capital rose by 48% year-on-year and by 14% since the previous quarter
Syndax Pharmaceuticals's return on assets has increased by 23% YoY and by 8% QoQ

Dividends

What is SNDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SNDX.

Financial health

How did Syndax Pharmaceuticals financials performed over time
The total assets is 10% more than the total liabilities
The total assets has contracted by 26% YoY and by 11% from the previous quarter
SNDX's current ratio is up by 24% since the previous quarter but it is down by 6% year-on-year
SNDX's equity has shrunk by 81% YoY and by 36% QoQ
The debt to equity has surged by 55% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.